UBS initiated coverage of Celldex (CLDX) with a Buy rating and $44 price target The firm says KIT inhibition is “differentiated in the underpenetrated” chronic spontaneous urticaria space. UBS sees a $3.8B market opportunity in CSU.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDX:
- Buy Recommendation for Celldex: Barzolvolimab’s Market Leadership and Efficacy Drive Positive Outlook
- Blueprint Medicines price target lowered to $124 from $135 at Wedbush
- Jasper Therapeutics price target lowered to $64 from $90 at BTIG
- JMP Securities healthcare analysts hold an analyst/industry conference call
- Jasper BEACON data ‘net positive,’ says BMO Capital